Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ORGO Stock Summary
Top 10 Correlated ETFs
ORGO
In the News
Why Organogenesis Holding Stock Plummeted by 18% Today
To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results.
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
Organogenesis (ORGO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2023 financial results will be reported after the market closes on Thursday, February 29th.
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for January 5th
ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.
New Strong Buy Stocks for January 5th
ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.
Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Reasons Why Small-Cap Stocks Can Surge in 2024: 5 Top Picks
Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Against this backdrop, Organogenesis (ORGO), Riskified (RSKD), Hooker Furniture Corporation (HOFT), Stoneridge (SRI) and VirTra (VTSI) emerge as winning picks.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Organogenesis (ORGO)
Organogenesis (ORGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
ORGO Financial details
ORGO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.81 | 3.14 | 3.65 | 3.47 | 3.3 | |
Net income per share | -0.44 | 0.16 | 0.73 | 0.12 | 0.04 | |
Operating cash flow per share | -0.36 | 0.06 | 0.48 | 0.19 | 0.24 | |
Free cash flow per share | -0.43 | -0.13 | 0.24 | -0.07 | 0.05 | |
Cash per share | 0.65 | 0.78 | 0.89 | 0.79 | 0.8 | |
Book value per share | 0.6 | 1.36 | 1.89 | 2.04 | 2.12 | |
Tangible book value per share | 0.1 | 0.8 | 1.46 | 1.66 | 1.78 | |
Share holders equity per share | 0.6 | 1.36 | 1.89 | 2.04 | 2.12 | |
Interest debt per share | 1.18 | 0.89 | 1.09 | 0.97 | 0.63 | |
Market cap | 446.56M | 811.27M | 1.19B | 349.89M | 536.74M | |
Enterprise value | 486.99M | 811.64M | 1.2B | 371.2M | 551.75M | |
P/E ratio | -11.04 | 47.07 | 12.59 | 22.53 | 108.54 | |
Price to sales ratio | 1.71 | 2.4 | 2.53 | 0.78 | 1.24 | |
POCF ratio | -13.32 | 119.29 | 19.13 | 14.07 | 17.36 | |
PFCF ratio | -11.23 | -56.56 | 38.55 | -38.71 | 81.91 | |
P/B Ratio | 8.03 | 5.55 | 4.9 | 1.32 | 1.93 | |
PTB ratio | 8.03 | 5.55 | 4.9 | 1.32 | 1.93 | |
EV to sales | 1.87 | 2.4 | 2.57 | 0.82 | 1.27 | |
Enterprise value over EBITDA | -24.33 | 23.2 | 13.44 | 9.21 | 13.87 | |
EV to operating cash flow | -14.53 | 119.34 | 19.43 | 14.93 | 17.85 | |
EV to free cash flow | -12.25 | -56.58 | 39.15 | -41.07 | 84.2 | |
Earnings yield | -0.09 | 0.02 | 0.08 | 0.04 | 0.01 | |
Free cash flow yield | -0.09 | -0.02 | 0.03 | -0.03 | 0.01 | |
Debt to equity | 1.81 | 0.58 | 0.55 | 0.47 | 0.29 | |
Debt to assets | 0.46 | 0.29 | 0.3 | 0.28 | 0.17 | |
Net debt to EBITDA | -2.02 | 0.01 | 0.21 | 0.53 | 0.38 | |
Current ratio | 2.1 | 2.56 | 2.77 | 2.97 | 2.8 | |
Interest coverage | -3.27 | 2.43 | 10.08 | 11.1 | 7.45 | |
Income quality | 0.83 | 0.38 | 0.65 | 1.6 | 6.25 | |
Dividend Yield | 0.13 | 0 | 0 | 0 | 0 | |
Payout ratio | -1.43 | 0 | 0.02 | 0.04 | 0 | |
Sales general and administrative to revenue | 0.76 | 0.59 | 0.52 | 0.62 | 0 | |
Research and developement to revenue | 0.06 | 0.06 | 0.07 | 0.09 | 0.1 | |
Intangibles to total assets | 0.21 | 0.2 | 0.12 | 0.11 | 0.1 | |
Capex to operating cash flow | 0.19 | -3.11 | -0.5 | -1.36 | -0.79 | |
Capex to revenue | -0.02 | -0.06 | -0.07 | -0.08 | -0.06 | |
Capex to depreciation | -0.66 | -2.83 | -1.87 | -1.88 | -1.04 | |
Stock based compensation to revenue | 0 | 0 | 0.01 | 0.01 | 0.02 | |
Graham number | 2.42 | 2.21 | 5.58 | 2.34 | 1.34 | |
ROIC | -0.17 | 0.11 | 0.25 | 0.04 | 0.02 | |
Return on tangible assets | -0.23 | 0.07 | 0.24 | 0.04 | 0.01 | |
Graham Net | -0.69 | -0.07 | -0.1 | -0.01 | -0.01 | |
Working capital | 65.71M | 106.13M | 144.97M | 147.59M | 144.54M | |
Tangible asset value | 9.25M | 86.69M | 187.59M | 216.11M | 234.02M | |
Net current asset value | -39.5M | 25.93M | 25.76M | 38.92M | 43.68M | |
Invested capital | 1.81 | 0.58 | 0.55 | 0.47 | 0.29 | |
Average receivables | 36.72M | 48.08M | 69.63M | 85.96M | 85.72M | |
Average payables | 23.78M | 25.88M | 26.36M | 30.83M | 31.53M | |
Average inventory | 18.12M | 25.36M | 26.41M | 24.9M | 26.52M | |
Days sales outstanding | 55.05 | 61.29 | 64.3 | 72.41 | 69.1 | |
Days payables outstanding | 136.43 | 97.73 | 93.77 | 112.36 | 90.91 | |
Days of inventory on hand | 110.14 | 116.2 | 79.97 | 86.13 | 83.6 | |
Receivables turnover | 6.63 | 5.96 | 5.68 | 5.04 | 5.28 | |
Payables turnover | 2.68 | 3.73 | 3.89 | 3.25 | 4.01 | |
Inventory turnover | 3.31 | 3.14 | 4.56 | 4.24 | 4.37 | |
ROE | -0.73 | 0.12 | 0.39 | 0.06 | 0.02 | |
Capex per share | -0.07 | -0.2 | -0.24 | -0.26 | -0.19 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.88 | 0.82 | 0.89 | 0.83 | 0.76 | |
Net income per share | 0.06 | -0.02 | 0.04 | 0.09 | 0 | |
Operating cash flow per share | 0.06 | -0.04 | 0.07 | 0.13 | 0.08 | |
Free cash flow per share | -0.02 | -0.1 | 0.01 | 0.08 | 0.06 | |
Cash per share | 0.78 | 0.68 | 0.69 | 0.75 | 0.8 | |
Book value per share | 2.03 | 2.01 | 2.07 | 2.11 | 2.13 | |
Tangible book value per share | 1.65 | 1.64 | 1.71 | 1.76 | 1.79 | |
Share holders equity per share | 2.03 | 2.01 | 2.07 | 2.11 | 2.13 | |
Interest debt per share | 0.95 | 0.94 | 0.95 | 0.95 | 0.62 | |
Market cap | 352.17M | 279.21M | 435.89M | 417.57M | 535.45M | |
Enterprise value | 373.48M | 312.87M | 471.73M | 444.37M | 550.46M | |
P/E ratio | 11.76 | -23.51 | 20.5 | 8.62 | -235.67 | |
Price to sales ratio | 3.05 | 2.59 | 3.72 | 3.85 | 5.37 | |
POCF ratio | 45.15 | -54.99 | 50.42 | 24.95 | 50.45 | |
PFCF ratio | -123.31 | -22.09 | 380.03 | 38.82 | 73.46 | |
P/B Ratio | 1.33 | 1.06 | 1.61 | 1.51 | 1.92 | |
PTB ratio | 1.33 | 1.06 | 1.61 | 1.51 | 1.92 | |
EV to sales | 3.23 | 2.91 | 4.02 | 4.09 | 5.52 | |
Enterprise value over EBITDA | 42.84 | 165.98 | 35.66 | 55.2 | 78.87 | |
EV to operating cash flow | 47.88 | -61.62 | 54.56 | 26.55 | 51.87 | |
EV to free cash flow | -130.77 | -24.75 | 411.27 | 41.31 | 75.52 | |
Earnings yield | 0.02 | -0.01 | 0.01 | 0.03 | 0 | |
Free cash flow yield | -0.01 | -0.05 | 0 | 0.03 | 0.01 | |
Debt to equity | 0.47 | 0.46 | 0.46 | 0.45 | 0.29 | |
Debt to assets | 0.28 | 0.27 | 0.28 | 0.27 | 0.17 | |
Net debt to EBITDA | 2.44 | 17.86 | 2.71 | 3.33 | 2.15 | |
Current ratio | 2.97 | 2.85 | 2.95 | 2.77 | 2.8 | |
Interest coverage | -138.77 | -6.13 | 16.41 | -18.13 | 1.29 | |
Income quality | 1.04 | 1.71 | 1.63 | 5.29 | -18.68 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0.01 | 0 | 0 | |
Sales general and administrative to revenue | 0.55 | 0 | 0.6 | 0 | 0 | |
Research and developement to revenue | 0.1 | 0.1 | 0.09 | 0.1 | 0.12 | |
Intangibles to total assets | 0.11 | 0.11 | 0.1 | 0.1 | 0.1 | |
Capex to operating cash flow | -1.37 | 1.49 | -0.87 | -0.36 | -0.31 | |
Capex to revenue | -0.09 | -0.07 | -0.06 | -0.06 | -0.03 | |
Capex to depreciation | -2.34 | -1.29 | -2.17 | -1.58 | -0.53 | |
Stock based compensation to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Graham number | 1.62 | 1.01 | 1.37 | 2.09 | 0.46 | |
ROIC | 0.01 | -0.01 | 0.01 | 0.03 | 0 | |
Return on tangible assets | 0.02 | -0.01 | 0.01 | 0.03 | 0 | |
Graham Net | -0.01 | -0.09 | -0.05 | -0.05 | -0.01 | |
Working capital | 147.59M | 140.75M | 142.98M | 144.09M | 144.54M | |
Tangible asset value | 216.11M | 215.37M | 224.18M | 230.99M | 234.02M | |
Net current asset value | 38.92M | 34.42M | 37.4M | 39.79M | 43.68M | |
Invested capital | 0.47 | 0.46 | 0.46 | 0.45 | 0.29 | |
Average receivables | 91.28M | 90.74M | 92.82M | 91.45M | 85.64M | |
Average payables | 35.14M | 31.32M | 28.85M | 27.09M | 28.75M | |
Average inventory | 24.73M | 25.16M | 25.45M | 26.63M | 28.08M | |
Days sales outstanding | 69.69 | 76.94 | 71.82 | 74.03 | 74.06 | |
Days payables outstanding | 107.33 | 102.53 | 93.67 | 93.47 | 86.76 | |
Days of inventory on hand | 82.27 | 86.39 | 86.74 | 97.38 | 79.79 | |
Receivables turnover | 1.29 | 1.17 | 1.25 | 1.22 | 1.22 | |
Payables turnover | 0.84 | 0.88 | 0.96 | 0.96 | 1.04 | |
Inventory turnover | 1.09 | 1.04 | 1.04 | 0.92 | 1.13 | |
ROE | 0.03 | -0.01 | 0.02 | 0.04 | 0 | |
Capex per share | -0.08 | -0.06 | -0.06 | -0.05 | -0.03 |
ORGO Frequently Asked Questions
What is Organogenesis Holdings Inc. stock symbol ?
Organogenesis Holdings Inc. is a US stock , located in Canton of Ma and trading under the symbol ORGO
What is Organogenesis Holdings Inc. stock quote today ?
Organogenesis Holdings Inc. stock price is $2.84 today.
Is Organogenesis Holdings Inc. stock public?
Yes, Organogenesis Holdings Inc. is a publicly traded company.